Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05307939
Other study ID # 21-434
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 24, 2022
Est. completion date March 24, 2025

Study information

Verified date January 2024
Source Memorial Sloan Kettering Cancer Center
Contact Linda Chen, MD
Phone 201-775-7447
Email chenl1@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable. In Arm B, the researchers will see whether patients who usually need 6-6.5 weeks of CRT can be selected by HPV ctDNA to receive 3 weeks of CRT.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 24, 2025
Est. primary completion date March 24, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 - ECOG 0-2 - HPV-16 squamous cell carcinoma of the oropharynx or HPV-16 head and neck squamous cell carcinoma of unknown primary . HPV status must be confirmed by in-situ hybridization. - HPV ctDNA detectable by HPV digital PCR (Naveris assay) with a minimum of 50 copies/mL pre-operatively. - Surgical resection of all gross disease with no gross disease visualized on post-operative imaging. o For patients with pT0 (unknown primary) evaluation for the primary should include PET/CT, direct laryngoscopy, ipsilateral tonsillectomy, and targeted biopsy. This should be followed by a neck dissection. - Two, undetectable (<1 copy/mL) post-operative HPV ctDNA within 2-6 weeks following surgery (blood drawn at least one week apart preferred). - A minimum of one of the following pathologic criteria: (Arm A) - AJCC 7 Stage: pT0N1-N2b, pT1N1, pT2N1, or =pT3 - AJCC 7 =pN2 - Lymphovascular invasion - Perineural invasion - Close pathologic margin (= 3 mm) - Signed informed consent form by the participant or their legally authorized representative (LAR). - A minimum of one of the following pathologic criteria (Arm B): - Microscopic positive margin - Extracapsular extension - Signed informed consent form by the participant or their legally authorized representative (LAR). Additional criteria for Arm B only: - Adequate hematologic function within 30 days prior to registration, defined as follows: - White Blood Count (WBC) = 2 K/mcL - Absolute neutrophil count (ANC) = 1,000 cells/mm3 - Platelets = 100,000 cells/mm3 - Hemoglobin = 8.0 g/dl; Note: The use of transfusion or other intervention to achieve Hgb = 8.0 g/dl is acceptable - Adequate renal function within 30 days prior to registration, defined as follows: - Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) = 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula: - CCr male = [(140 - age) x (wt in kg)] divided by [(Serum Cr mg/dl) x (72)] - CCr female = 0.85 x (CrCl male) - Adequate hepatic function within 30 days prior to registration, defined as follows: - Bilirubin < 2 mg/dl o AST or ALT < 3 x the upper limit of normal - Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential Exclusion Criteria: - Metastatic disease - Non-HPV16 genotype (i.e. HPV-18,-31, -33, -35) - Patients who receive surgery at outside institution. Exceptions can be made for high-volume surgical centers at the discretion of the PI/co-PI - Prior head and neck radiation - Patients without pre-operative HPV ctDNA or pre-operative HPV ctDNA = 50 copies/mL - Subjects with simultaneous primary cancers outside of the oropharynx o Note: Exceptions can be made for patients with simultaneous primaries outside of the oropharynx if determined by the PI/Co-PI, then the patient can proceed with protocol activities - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years is 90% or greater o Note: Exceptions can be made for patients with prior invasive malignancy if determined by the PI/Co-PI, then the patient can proceed with protocol activities - Prior systemic chemotherapy for the study cancer o Note: prior chemotherapy for a different cancer is allowable - Severe, active co-morbidity defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of registration - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects - Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
HPV ctDNA Assay
HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
MRI Studies
Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
Behavioral:
EORTC QLQ H&N 35 and C30
The EORTC QLQ H&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
MDADI-HN
The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
COST-FACIT
Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
Radiation:
Intensity-Modulated Radiation Therapy (Arm A)
59.4-60 Gy in 1.8-2 Gy fractions: CTV_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
Combination Product:
Chemoradiation (Arm B)
30 Gy in 2 Gy fractions: CTV_primary, CTV_node-positive neck, CTV_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge New Jersey
United States Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack New York
United States Memorial Sloan Kettering Westchester (Limited Protocol Activites) Harrison New York
United States Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York
United States Memorial Sloan Kettering Nassau (Limited protocol activities) Rockville Centre New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologically confirmed progression free survival To estimate pathologically confirmed progression free survival (pPFS) two years post-operatively in HPV associated OPC patients who undergo active surveillance. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT01105000 - Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
Recruiting NCT06147388 - Regression of Cervical Precancerous Lesions and Associated Risk Factors
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Recruiting NCT06109870 - Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening N/A
Completed NCT03082950 - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting NCT01512784 - Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults Phase 3
Recruiting NCT05363709 - BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients Phase 2
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT05996016 - Gut and Vaginal Microbiota Profile Study for HIV Women
Completed NCT05907187 - Research in Ethno-Medicine and Education (REMED) N/A
Completed NCT05616767 - Prevention and Screening for Early Detection of HPV-related Cancers in Gay and Bisexual Men in Tanzania N/A
Completed NCT02247999 - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Terminated NCT01468636 - A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Phase 4
Active, not recruiting NCT04965792 - Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Active, not recruiting NCT05006833 - Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness N/A
Enrolling by invitation NCT06120205 - SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening N/A
Recruiting NCT05208710 - PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers Early Phase 1
Completed NCT05462249 - Impact of Catch-up HPV Vaccination